The initial success of Sildenafil undeniably revolutionized the drug landscape, but betting in companies heavily reliant on off-patent versions presents a challenging picture. Although early earnings were impressive, the expiration of patents and the emergence of cheaper alternatives have eroded sales. Therefore, a thorough evaluation of ongoing fi